Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Acorda Therapeutics will Expand Footprint in New York’s Lower Hudson Valley, Creating 190 Jobs

06/27/2011
Governor Andrew M. Cuomo has announced that biotechnical drug manufacturer Acorda Therapeutics, Inc. will relocate to a new facility in Westchester County, investing $36 million and potentially creating 190 new jobs.

Empire State Development (ESD) will provide Acorda with up to $5.2 million in Excelsior Jobs Program tax benefits as an incentive for job creation.

Accorda develops therapies for multiple sclerosis, spinal cord injury and related nervous system disorders. The company's new 139,000 square foot facility will be located in the Ardsley Park life science campus, owned and managed by BioMed Realty Trust, Inc. The company will relocate to the new facility from its current location in nearby Hawthorne, retaining 159 employees bringing total employment to nearly 350 employees.

Acorda is one of more than 60 biotech companies located across the seven counties that comprise "NY BioHud Valley", the branded name for the robust biotech corridor that is sprouting in the Hudson Valley area between Albany and New York City.

U.S. Senator Charles E. Schumer said, "This significant investment by BioMed Realty Trust continues the Hudson Valley's transformation into an epicenter for biotechnology companies and the high-paying jobs that come with them. Acorda's decision to remain in the Hudson Valley and potentially create up to 190 brand new jobs in a booming sector of our economy affirms the area continues to be attractive for innovative companies. I applaud BioMed for investing in a second life science site which will make 'NY BioHud Valley' one of the fastest growing biotech regions in the country."

Exclusive Research